Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.8K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.8K
Cancer02:18

Cancer

53.3K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: MYC Expression in Concert With BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.

PloS one·2018
Same author

Molecular characterization of nine suppressors of cytokine signaling (SOCS) genes from yellow catfish Pelteobagrus fulvidraco and their changes in mRNA expression to dietary carbohydrate levels.

Fish & shellfish immunology·2018
Same author

Staining Traditional Colloidal Gold Test Strips with Pt Nanoshell Enables Quantitative Point-of-Care Testing with Simple and Portable Pressure Meter Readout.

ACS applied materials & interfaces·2018
Same author

Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection.

Journal of translational medicine·2018
Same author

Microfluidic Preconcentration Chip with Self-Assembled Chemical Modified Surface for Trace Carbonyl Compounds Detection.

Sensors (Basel, Switzerland)·2018
Same author

Efficacy of Telephone Follow-Up in Children Tonsillectomy with Day Surgery.

Indian journal of pediatrics·2018

Related Experiment Video

Updated: Dec 31, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.5K

Icotinib: efficacy in different solid tumors and gene mutations.

Qian Zhao1, Jie Cheng1, Pingping Chen2

  • 1Department of Pharmacy, Hebei Hospital of Chinese Medicine.

Anti-Cancer Drugs
|January 15, 2020
PubMed
Summary

Icotinib effectively treats non-small cell lung cancer with sensitive epidermal growth factor receptor mutations. It also shows promise in other cancers with specific epidermal growth factor receptor alterations, like esophageal cancer.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K

Related Experiment Videos

Last Updated: Dec 31, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.5K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Icotinib is a first-generation epidermal growth factor receptor (EGFR) inhibitor approved in China for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations.
  • EGFR alterations are implicated in various solid tumors, driving cancer growth and progression.

Purpose of the Study:

  • To review the efficacy of icotinib in solid tumors characterized by diverse epidermal growth factor receptor alterations.
  • To consolidate current understanding of icotinib's therapeutic potential beyond its primary indication.

Main Methods:

  • Literature review of studies evaluating icotinib in solid tumors.
  • Analysis of clinical data on icotinib's efficacy across different tumor types and EGFR mutation statuses.
  • Synthesis of findings related to treatment response and outcomes.

Main Results:

  • Icotinib demonstrates approved efficacy in NSCLC with EGFR-sensitive mutations.
  • Moderate activity is observed in NSCLC with rare, non-resistant EGFR mutations.
  • Icotinib shows potential in esophageal cancer with EGFR amplification or overexpression.

Conclusions:

  • Icotinib is a valuable therapeutic option for NSCLC patients with EGFR-sensitive mutations.
  • Further investigation into icotinib's role in other EGFR-altered solid tumors is warranted.
  • Icotinib's efficacy is linked to specific epidermal growth factor receptor alterations.